Daily Respiratory Research Analysis
Today's most impactful respiratory research spans imaging standardization, screening risk stratification, and biomarker-driven prognosis. A multisociety Radiology consensus defines what to acquire and how to report CTA for suspected acute pulmonary embolism. A Thorax analysis from the SUMMIT screening program compares volume versus diameter thresholds for malignancy prediction in solid nodules, while a Critical Care Medicine study identifies soluble ICAM-1 as a central biomarker linked to outcom
Summary
Today's most impactful respiratory research spans imaging standardization, screening risk stratification, and biomarker-driven prognosis. A multisociety Radiology consensus defines what to acquire and how to report CTA for suspected acute pulmonary embolism. A Thorax analysis from the SUMMIT screening program compares volume versus diameter thresholds for malignancy prediction in solid nodules, while a Critical Care Medicine study identifies soluble ICAM-1 as a central biomarker linked to outcomes in pediatric ARDS/acute respiratory failure.
Research Themes
- Standardizing CTA acquisition and reporting for suspected pulmonary embolism
- Optimizing size/volume thresholds for malignancy prediction in LDCT lung cancer screening
- Biomarker networks and prognosis in pediatric ARDS/acute respiratory failure
Selected Articles
1. Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening.
In the SUMMIT screening cohort (n=11,355), baseline solid nodules had a 3.8% crude malignancy risk. Nodules below 6 mm in diameter or below 100 mm³ volume carried very low malignancy risk, supporting volumetry-based thresholds for management at baseline LDCT.
Impact: This large prospective screening analysis directly informs threshold selection (diameter vs volume) for nodule malignancy risk, a critical operational point in LDCT lung cancer screening pathways.
Clinical Implications: Volumetry-based thresholds (e.g., <100 mm³ as very low risk) can reduce unnecessary follow-up for tiny nodules while focusing resources on higher-risk lesions, potentially streamlining LCS protocols.
Key Findings
- Baseline crude malignancy risk for solid nodules was 3.8% across 11,355 participants.
- Solid nodules <6 mm in long-axis or <100 mm³ had very low malignancy risk at baseline.
- Findings support volumetry as a robust basis for malignancy risk stratification in LCS.
Methodological Strengths
- Large prospective screening cohort with standardized LDCT acquisition
- Direct comparison of volume- and diameter-based thresholds at baseline
Limitations
- Abstract details on full threshold performance metrics and longitudinal outcomes are truncated/not provided
- Observational design; external validation in other LCS programs is needed
Future Directions: Validate volumetry thresholds across diverse LCS programs and integrate with AI-driven risk models; assess downstream impacts on interval cancer rates and resource utilization.
BACKGROUND: Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for assessing malignancy in solid nodules at baseline low-dose CT (LDCT) in a lung cancer screening (LCS) programme. METHODS: This was an observational study using data from the SUMMIT Study, a prospective longitudinal study investigating LDCT for LCS. Participants were 55-77 years old and met either the United States Preventative Services Task Force (2013) criteria or had a PLCO RESULTS: 11 355 participants were included. Crude risk of malignancy in solid nodules at baseline LDCT was 3.8% (228/5929). Risk of malignancy in solid nodules <6 mm long-axis diameter or <100 mm CONCLUSIONS: Solid nodules <100 mm
2. Optimal Approach to Performing and Reporting Computed Tomography Angiography for Suspected Acute Pulmonary Embolism: A Clinical Consensus Statement of the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, the Fleischner Society, the Association for Acute Cardiovascular Care (ACVC) and the European Association of Cardiovascular Imaging (EACVI) of the ESC, Endorsed by European Respiratory Society (ERS), Asian Society of Thoracic Radiology (ASTR), European Society of Thoracic Imaging (ESTI), and Society of Thoracic Radiology (STR).
A multisociety expert panel defines best practices for performing and reporting CTA in suspected acute PE, including standardized nomenclature, core diagnostic and prognostic findings, and an image atlas with assessment instructions. Implementation aims to harmonize reports and guide management to improve PE outcomes.
Impact: Standardized CTA reporting for PE can directly reduce variability, improve risk stratification, and streamline multidisciplinary decision-making across institutions.
Clinical Implications: Radiologists and clinicians can adopt a uniform core set of CTA findings (diagnostic and prognostic) and structured reports, enabling consistent communication and management pathways for suspected PE.
Key Findings
- Provides updated CTA acquisition techniques and standardized nomenclature for PE.
- Defines a core set of diagnostic and prognostic CTA findings and recommended report content.
- Includes a detailed image atlas and lay-language guidance to support consistent assessment and communication.
Methodological Strengths
- Multisociety, multidisciplinary consensus spanning cardiology, radiology, and respiratory societies
- Comprehensive scope including techniques, interpretation, and structured reporting templates
Limitations
- Consensus/guidance rather than primary empirical data; real-world implementation studies are needed
- Resource and workflow variability across centers may challenge uniform adoption
Future Directions: Evaluate the impact of structured CTA reporting on diagnostic accuracy, risk stratification, treatment timeliness, and outcomes; develop EHR-integrated templates and AI decision support.
CT angiography (CTA) is the modality used most frequently for diagnosing acute pulmonary embolism (PE). Given the vast amount of information that can be extracted from CTA, the CTA report should be written in a way that conveys all relevant findings using standardized nomenclature and definitions. Broad consensus on a core set of CTA findings that are relevant for all PE patients is not currently available. This clinical consensus statement written by the European Society of Cardiology (ESC) Working Group on Pulmonary Circulation & Right Ventricular Function, the Fleischner Society, and the Association for Acute Cardiovascular Care and the European Association of Cardiovascular Imaging of the ESC provides a current update of CTA techniques, a definition of often-used nomenclature and recommendations on the proposed content of CTA reports along with a detailed image atlas with instructions on how to assess all relevant CTA findings and a lay language guidance on the meaning of these findings. Ultimately, upon implementation, this document is expected to standardize CTA radiology reports with respect to diagnostic and prognostic CT imaging findings to guide and harmonize management decisions, ultimately improving outcomes of care for PE patients. This article has been co-published with permission in the
3. Plasma Soluble Intercellular Adhesion Molecule-1 Has a Central Role in Biomarker Network Analysis and Is Associated With Poor Outcomes in Two Distinct Pediatric Cohorts of Acute Respiratory Distress Syndrome and Acute Respiratory Failure.
Across two multicenter pediatric cohorts (PALI and CAF-PINT; total n=465), higher plasma sICAM-1 measured within 72 hours was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days. Network analysis identified sICAM-1 as a hub biomarker alongside TIMP-1, TNFR1, and IL-8, underscoring endothelial/leukocyte pathways in ARDS pathophysiology.
Impact: Identifying sICAM-1 as a reproducible prognostic biomarker and network hub across cohorts supports its use in risk stratification and as a potential therapeutic target in pediatric ARDS.
Clinical Implications: Early sICAM-1 measurement may refine prognostication and selection for trials targeting endothelial dysfunction; panels including TIMP-1, TNFR1, IL-8 could enhance predictive performance.
Key Findings
- Higher plasma sICAM-1 within 72 hours associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days in both cohorts.
- Network analysis identified sICAM-1 (centrality 0.74) as a hub along with TIMP-1 (0.99), TNFR1 (0.83), and IL-8 (0.74).
- Findings highlight endothelial/leukocyte trafficking and inflammation as key ARDS pathobiology axes.
Methodological Strengths
- Two independent multicenter prospective cohorts with consistent associations
- Network-based systems analysis contextualizing biomarker interactions
Limitations
- Secondary analysis; causality cannot be inferred
- Pediatric cohorts may limit generalizability to adult ARDS
Future Directions: Prospective validation of sICAM-1–based risk panels and interventional trials targeting endothelial/leukocyte pathways; exploration of temporal dynamics and thresholds for clinical decision-making.
OBJECTIVES: Intercellular adhesion molecule-1 (ICAM-1) is a glycoprotein expressed on immune, endothelial, and epithelial cells. In the setting of inflammation, it becomes upregulated and spliced into a soluble form (soluble ICAM-1 [sICAM-1]). This study examined the association of sICAM-1 with clinical outcomes in two large pediatric cohorts with acute respiratory distress syndrome (ARDS) and acute respiratory failure (ARF) and examined the relationships between sICAM-1 and other protein biomarkers utilizing network analysis to contextualize its role in ARDS pathophysiology. DESIGN: Secondary analysis of prospective cohort studies. SETTING: Multicenter PICUs. PATIENTS OR SUBJECTS: Critically ill children with ARDS (Pediatric Acute Lung Injury [PALI], 2008-2014) and ARF (Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial [CAF-PINT], 2012-2016). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: sICAM-1 levels were measured from plasma collected within 72 hours of diagnosis. The primary outcome was in-hospital mortality, and secondary outcomes included multiple organ dysfunction and ventilator-free days. We constructed a biomarker correlation-based network that included sICAM-1 and 32 plasma biomarkers reflective of inflammation, endothelial and epithelial injury, and extracellular matrix degradation. Key biomarkers with centrality metrics in the top 10% (≥ 90th percentile) were defined as critical hubs within the network. The study included 214 children from PALI and 251 from CAF-PINT. In-hospital mortality was 18% and 14%, respectively. Baseline median oxygenation index ratios were 10 (interquartile range [IQR], 5.6-19.7) and 8.5 (IQR, 3.5-17.7). Higher plasma sICAM-1 was associated with in-hospital mortality, multiple organ dysfunction, and fewer ventilator-free days in each of the two cohorts (all p < 0.05). Tissue inhibitor of metalloproteinase-1 (composite centrality, 0.99), tumor necrosis factor receptor-1 (0.83), sICAM-1 (0.74), and interleukin-8 (0.74) were identified as network hubs. CONCLUSIONS: Elevated sICAM-1 levels were associated with poor outcomes in two separate cohorts of ARDS and ARF patients. Network analysis revealed sICAM-1 as a central hub, characterized by high centrality metrics. These findings underscore the multifaceted role of sICAM-1 in leukocyte transmigration, inflammation, and endothelial dysfunction and highlight its critical role in ARDS pathophysiology.